Marginal zone lymphoma represents about 10% of all non-Hodgkin lymphomas (NHLs). 33% of patients with acquired angioedema (AAE) due to acquired C1-inhibitor (C1-INH) deficiency (C1-INH-AAE) have or will develop NHLs. C1-INH-AAE is a rare condition. We report the follow-up of 72 C1-INH-AAE patients, followed for a median of 15 years (range 1-24). Median age was 71 (range 64-79) years; median age at onset of angioedema symptoms was 57Á5 (range 50-66) years and it was 63 [range 45-80) years at diagnosis]. Twenty patients were diagnosed with low-grade non-follicular B-cell lymphomas (75% were splenic MZL), one with follicular and three with high-grade lymphomas (two diffuse large B-cell lymphomas and one mantle cell lymphoma). Fifteen NHLs were diagnosed at onset of AAE or thereafter (3 months to 7 years), eight had already been diagnosed at onset of angioedema. Two of 24 patients remain on watchful wait. Thirthen of 24 received chemotherapy, two received rituximab. Three underwent splenectomy. All 18 patients receiving therapy for NHL experienced post-treatment reduction in AAE symptoms. Our study suggests that clonal B-cell proliferation is the pathology underlying AAE leading to production of C1-INH-neutralizing autoantibodies and to NHLs. The postgerminal centre origin of NHL suggests that immune stimulation may contribute to lymphomagenesis.
Angioedema due to an acquired deficiency of the inhibitor of the first component of complement (C1-INH) is a rare syndrome usually identified as acquired angioedema (AAE). The clinical features of C1-INH deficiency, which can also be of genetic origin (hereditary angioedema, HAE), include recurrent, self-limiting local swellings involving the upper respiratory tract and the gastrointestinal tract with severe abdominal pain (Zingale et al, 2006) . Swelling is due to local accumulation of bradykinin released from high molecular weight kininogen upon uncontrolled activation of plasma kallikrein deprived of its major physiological inhibitor, C1-INH (Cugno et al, 2009 ). The precise aetiology of acquired C1-INH deficiency remains undefined, but the majority of patients have an underlying Bcell disorder, which appears to be the crucial underlying pathology driving the consumption of C1-INH. These B-cell disorders range from production of anti-C1-INH autoantibodies to mon-oclonal gammopathies of uncertain significance (MGUS) to Non-Hodgkin Lymphomas (NLHs) (Cicardi et al, 1996 (Cicardi et al, , 2003 Castelli et al, 2007; Branellec et al, 2012; Lam et al, 2012) . The low levels of C1-INH due to its consumption by pathological lymphatic tissue or its autoantibody-mediated inactivation are associated with hyper-activation of the complement or contact system, which may further consume C1-INH. Standard treatment for AAE attacks is replacement therapy with plasmaderived C1-INH concentrate (pdC1-INH). However, some patients with AAE become progressively less responsive to pdC1-INH treatment (Cicardi et al, 1996; Castelli et al, 2007) , possibly due to anti-C1-INH autoantibody development.
Growing experimental evidence suggests that microenvironmental interactions driven by inflammatory and infectious conditions favour the development or promotion of specific subtypes of indolent non-follicular NHLs (marginal zone lymphomas, MZLs; lymphoplasmatycic lymphomas, LPLs; small lymphocytic lymphomas, SLLs). This evidence suggests a role for chronic immune stimulation, either from persistent microbial infections or from autoantigens, in B cell transformation (Wotherspoon et al, 1991; Franklin et al, 2006) .
Further insight on the association between autoimmune disorders, antigen stimulation and NHL subtypes may help in understanding the underlying biology of antigen-driven lymphomagenesis, both in general and specific settings. Here we report data from our cohort of 72 AAE patients with a 33% rate of lymphoproliferative diseases. Most of them are indolent non-follicular B cell lymphoproliferative disease (INFBCLs,) suggesting a likely antigen-driven pathogenetic mechanism.
Patients and methods
Seventy-two AAE patients were included, 32 of which have already been described (Castelli et al, 2007) . The diagnosis was based on a history of recurrent angioedema without urticaria, which began during or after the fourth decade of life, absence of family history of angioedema, and plasma levels of C1-INH function below 50% of normal. Median age at onset of angioedema symptoms was 57Á5 (range 50-66) years and diagnosis was made at a median age of 63 (range 55-72) years. Fifteen of 24 (62Á5%) were diagnosed at onset of AAE or thereafter (3 months to 7 years). Face oedema was the most frequent location reported by 83% of patients; 69% of patients reported peripheral/abdominal attacks and 58% reported oral mucosa and/or glottis attacks. Seventy nine per cent of patients had their acute attacks treated with one of the specific treatments: 86% used pdC1-INH, 46% used Icatibant. C1-INH-auto antibodies were detected in 71% of patients that used pdC1-INH; 24% of these patients became non-responsive to pdC1-INH and switched to Icatibant. Twenty-four of these patients had histologically confirmed diagnosis of NHL according to the WHO classification (Swerdlow et al, 2008) Patients were followed for a median of 15 years (range: 1-24). The following clinical data were collected from the medical records: patient demographics, complete blood cell counts, plasma lactic dehydrogenase (LDH) level, hepatitis B virus (HBV) and hepatitis C virus (HCV) serology, Ann Arbor Stage, International Prognostic Index (IPI), Follicular Lymphoma IPI (FLIPI), bone marrow findings, the presence of B symptoms, Eastern Cooperative Oncology Group (ECOG) performance status, date of diagnosis, type of treatment, treatment response, date of relapse, date of last follow-up and cause of death and AAE status after lymphoma treatment.
Complement parameters were determined on serum or plasma samples stored at À80°C until tested. C1-INH, C4, C3 and C1q antigens were measured by radial immunodiffusion (Nor Partigen, Low Partigen for C1q Behring, Marburg, Germany). C1-INH antigenic and C4 were quantified using radial immunodiffusion or nephelometry; C1-INH function was measured using a chromogenic or an immunoenzimatic assay. Results were normalized as a percentage of normal value (functional C1-INH normal range 70-130%; antigenic C1-INH normal range 70-115%; antigenic C4 normal range 60-140%). Autoantibodies to C1-INH in serum were measured by enzyme-linked immunosorbent assay (ELISA) using the method described by Alsenz et al (1987) with slight modifications (Alsenz et al, 1987; Cicardi et al, 1996) .
Pathological classification of lymphoproliferative disorders associated with AAE
Haematoxylin-eosin stained slides were reviewed. Immunohistochemical staining using CD3, CD20, CD5, CD 10, CD23, BCL6 and cyclin D1 was performed on the diagnostic tissue biopsy in all patients with a diagnosis of lymphoproliferative disease. Lymphoproliferative disorders were classified according to the WHO classification (Swerdlow et al, 2008) .
Results
Twenty-four of 72 AAE patients (33%) had an underlying Bcell NHL. Fifteen of 24 (62Á5%) were diagnosed at onset of AAE or thereafter (3 months to 7 years). The remaining nine were diagnosed before the onset of AAE symptoms. According to the WHO classification (Swerdlow et al, 2008) , 21 were indolent NHL and three aggressive NHL (two diffuse large B-cell lymphomas and one mantle cell lymphoma). Indolent NHLs were splenic MZL (SMZL, n = 15), LPL (n = 3), SLL (n = 2), follicular lymphoma (n = 1) ( Fig 1) . Serological evidence of HCV infection was detected only in 1 AAE patient with NHL. The clinical characteristics of AAE patients with indolent non-follicular NHL are reported in Table I .
Autoantibodies to C1-INH were detected in 13 of 24 (54%) NHL patients, including 12/15 (80%) cases with a diagnosis of SMZL. 
Treatment outcome
Thirteen of the 20 patients with INFBCLs received systemic therapy alone. Chemotherapy regimens included: nonanthracycline-containing single agent regimen [chlorambucil or cyclophosphamide, vincristine and prednisone (CVP)] and anthracycline-containing regimen [cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP)]. Five patients were treated with bendamustine and rituximab and achieved complete remission. Two patients received rituximab alone.
All three patients with high-grade malignancies were treated with anthracycline-containing regimens (CHOP and Rituximab) and all three died of lymphoproliferative disease progression.
Three patients were treated with splenectomy alone, achieving complete remission at 5, 6 and 2 years of followup, respectively. Two patients are still in watchful wait due to stable disease. One patient with SMZL and concomitant HCV infection is currently receiving interferon a and ribavirin for viral eradication in preparation of possible chemotherapy. AAE patients did not seem to experience a significantly different rate of response to treatment as compared to patients with lymphoproliferative disease alone.
All patients treated with chemotherapy achieved, during therapeutic regimen or during remission, long lasting reduction of angioedema symptoms. For 12 of 18 patients, preand post-treatment complement parameters were available. All but one showed post-treatment improvement of complement abnormalities (Table II) . Several lymphoproliferative disorders appear to develop from transformation of a polyclonal proliferation of lymphocytes responding to antigenic and/or immunological drivers into a monoclonal/neoplastic population. This model has emerged with the description of several lymphomas developing in the context of chronic antigen-dependent immune stimulation, as reported for some infectious agents (e.g. H pylori-associated gastric mucosa-associated lymphoid tissue lymphoma, HCV-associated lymphoproliferative diseases) or autoimmune drivers (e.g. Sj€ ogren-associated lymphoproliferative diseases). In this study, we found that AAE is associated with an increased risk of NHL compared to general population. Interestingly, this study also suggests that the risk of lymphoproliferative disease is confined to specific histotypes that are rare in the general population (Armitage & Weisenburger, 1998) . Our finding is supported by additional scattered reports showing high prevalence of INFBCL, especially MZL and SMZL in patients with AAE (Sugisaki et al, 2007; Lam et al, 2012; Ates et al, 2015) .
Discussion
Our series is the largest reported to date and confirms that SMZL represents the most common histotype among AAE patients, with a frequency of 75% of INFBCL (15/20 indolent lymphoproliferative disease) and of 62Á5% of all lymphopro- liferative diseases identified. Histologically, the marginal zone surrounding the follicular areas is expanded and neoplastic cells have cytological and phenotypical features of marginal zone lymphocytes, clearly distinguishing them from the lymphocytes present in the follicular centre or mantle cell area (Troussard et al, 1996) . Despite being aware of the undeniable limits of histology, we speculate that the post-germinal origin of INFBCLs, especially MZL, might suggest an antigen-driven mechanism of lymphomagenesis in AAE patients. Some experimental studies pointed to NOTCH and NF-jB signalling as a strong driver of autoimmunity and lymphoproliferation and further research is needed to investigate the role of the activation of these pathways for lymphomagenesis in our AAE population (Rossi et al, , 2012 .
Next-generation sequencing studies have identified somatic mutations of myeloid differentiation primary response 88 (MYD88), a key component of the Toll-like receptor signalling machinery, in $ 90% of LPL and in MZLs. There is evidence to consider MYD88 L265P mutation as the first genetic hit that induces signalling cascades leading to NF-jB and JAK-STAT3 activation [with further enhancement due to Bruton tyrosine kinase (BTK) activation]. Additional genetic and epigenetic hits follow over time, with final B-cell deregulation and tumour progression (Poulain et al, 2013; Yang et al, 2013) .
MYD88 is mutated in a variety of mature B-cell tumours. Among indolent B-cell malignancies, MYD88 mutations tend to cluster with LPL/Waldenstr€ om macroglobulinaemia, where they occur in~90% of cases (Spina et al, 2015) . MYD88 mutations are also present in a significant fraction of IgM-secreting monoclonal gammopathies of undetermined significance (MGUS), where they are currently detected iñ 60-80% of cases, thus pointing to MYD88 mutations as an early genetic event in the development of lymphoplasmatycic tumours. Rare MYD 88 mutations are also found in SMZL and CLL. Among aggressive B-cell malignancies, MYD88 mutations have been identified in~30% of DLBCL (Fabbri et al, 2011; Rossi et al, 2012; Xu et al, 2014) .
Despite the reported association between INFBCL (especially MZL and LPL) and HCV infection , in our case series only one patient had HCV infection.
Autoimmune manifestations, including immune-mediated pancytopenia, haemolytic anaemia, immune-mediated thrombocytopenia, skin blistering disease, immunemediated neuropathies and autoantibodies to clotting factors may be included in the lymphoproliferative disorders (Castelli et al, 2002 (Castelli et al, , 2012 Zhang et al, 2006; Ramchandren & Lisak, 2010; Seffo & Daw, 2010) . MZL and SLL are particularly frequent in autoimmune manifestations, especially in MZL patients with a strict IGHV1-2 gene frequency (Chiorazzi et al, 2005; Hodgson et al, 2011; Brisou et al, 2014) .
Autoantibodies to C1-INH were detectable in nine of 15 patients with SMZL, one of who had a concomitant autoimmune haemolytic anaemia. This finding suggests that auto reactivity to this protein is not part of a generic tendency to autoimmunity, but a specific feature of the disease. Further investigations are needed to detail the effect of this protein on lymphocyte proliferation.
In conclusion, our study suggests that B-cell proliferation, frequently with clonal characteristics, is associated with acquired C1-INH deficiency and can be responsible for the production of neutralizing autoantibodies as well as for increased risk of lymphoproliferative disease. The post-germinal centre origin of most of lymphomas observed in our population seems to suggest that a chronic immune stimulation may contribute to lymphomagenesis. C1-INH belongs to the protein family of serine protease inhibitors and undergoes major structural changes to interact with its target proteases (Silverman et al, 2001) . Hence, we speculate that a still unknown event causes abnormal persistence of hidden epitopes not recognized as 'self' during inhibitor-protease interaction and initiates the autoimmune response that cross-reacts with the native protein.
